Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15645
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Theravance Biopharma Inc (TBPH) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company that focuses on the discovery, development, and marketing of organ-selective medicines for the treatment of inflammation and immune system disorders. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis; myelofibrosis; concurrent bacteremia; rheumatoid arthritis; and blood pressure. Its Yupelritm (revefenacin) obtained the US FDA approval for the treatment of chronic obstructive pulmonary disease (COPD) in the US. The company has subsidiaries in the US, Ireland and the UK. Theravance Biopharma is headquartered in South San Francisco, California, the US.

Theravance Biopharma Inc Key Recent Developments

Feb 26,2019 Theravance Biopharma announces fourth quarter and full year 2018 financial results
Jan 07,2019 Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Dec 04,2018 Theravance Biopharma to highlight innovative early research and clinical development at R&D day on December 12 in New York
Nov 08,2018 Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Theravance Biopharma Inc – Key Facts
Theravance Biopharma Inc – Key Employees
Theravance Biopharma Inc – Key Employee Biographies
Theravance Biopharma Inc – Major Products and Services
Theravance Biopharma Inc – History
Theravance Biopharma Inc – Company Statement
Theravance Biopharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Theravance Biopharma Inc – Business Description
R&D Overview
Theravance Biopharma Inc – Corporate Strategy
Theravance Biopharma Inc – SWOT Analysis
SWOT Analysis – Overview
Theravance Biopharma Inc – Strengths
Theravance Biopharma Inc – Weaknesses
Theravance Biopharma Inc – Opportunities
Theravance Biopharma Inc – Threats
Theravance Biopharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Theravance Biopharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 26, 2019: Theravance Biopharma announces fourth quarter and full year 2018 financial results
Jan 07, 2019: Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Dec 04, 2018: Theravance Biopharma to highlight innovative early research and clinical development at R&D day on December 12 in New York
Nov 08, 2018: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
Nov 07, 2018: Theravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference
Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update
Oct 08, 2018: Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV (telavancin) at IDWeek
Sep 17, 2018: Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018[Newswire : Healthcare-BW]
Sep 17, 2018: AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01[Newswire : Healthcare-BW]
Sep 17, 2018: Delos Adds Technology Business Leader Anthony Antolino as Chief Commercial Officer[Newswire : Healthcare-BW]
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Theravance Biopharma Inc, Key Facts
Theravance Biopharma Inc, Key Employees
Theravance Biopharma Inc, Key Employee Biographies
Theravance Biopharma Inc, Major Products and Services
Theravance Biopharma Inc, History
Theravance Biopharma Inc, Subsidiaries
Theravance Biopharma Inc, Key Competitors
Theravance Biopharma Inc, Ratios based on current share price
Theravance Biopharma Inc, Annual Ratios
Theravance Biopharma Inc, Annual Ratios (Cont...1)
Theravance Biopharma Inc, Interim Ratios
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Theravance Biopharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Theravance Biopharma Inc, Performance Chart (2014 - 2018)
Theravance Biopharma Inc, Ratio Charts
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on …
  • Samsung Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務分析
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Zion Oil & Gas Inc (ZN):企業の財務・戦略的SWOT分析
    Summary Zion Oil & Gas Inc (Zion Oil) is an oil and gas company that explores and produces oil and gas properties in Israel. The company offers services such as geophysical, geological, and other science-based studies and surveys to support oil and gas exploration and development services. It holds …
  • GEO Specialty Chemicals Inc:企業の戦略的SWOT分析
    GEO Specialty Chemicals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • PsychoGenics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PsychoGenics Inc (PsychoGenics) is a preclinical contract research organization that offers treatment for CNS and orphan disorders.The company’s capabilities include electrophysiology, behavioral testing, translational EEG, molecular biology, quantitative histology and microdialysis. Its pro …
  • Shire Plc (SHP)-製薬・医療分野:企業M&A・提携分析
    Summary Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas …
  • Jindal Hotels Ltd:企業の戦略・SWOT・財務情報
    Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Dermira Inc (DERM):医療機器:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Promethera Biosciences SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Promethera Biosciences SA (Promethera) is a developer of cell therapy products for the treatment of liver diseases. The company provides products which are developed on its proprietary progenitor cell type. It offers products such as promethera hepastem and promethera hepascreen, among other …
  • PUMA SE:企業の戦略・SWOT・財務情報
    PUMA SE - Strategy, SWOT and Corporate Finance Report Summary PUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Transocean Ltd (RIG):石油・ガス:M&Aディール及び事業提携情報
    Summary Transocean Ltd (Transocean) is a provider of offshore contract drilling services to the oil and gas industry. The company specializes in the technically demanding regions of the global offshore drilling business with a particular focus on deepwater and harsh environment drilling services. Tr …
  • PartnerRe Ltd.:企業の戦略・SWOT・財務情報
    PartnerRe Ltd. - Strategy, SWOT and Corporate Finance Report Summary PartnerRe Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • KCC Corp (002380):企業の財務・戦略的SWOT分析
    KCC Corp (002380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mednax Inc (MD):製薬・医療:M&Aディール及び事業提携情報
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • Genentech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology …
  • NBT Bancorp Inc:企業の戦略・SWOT・財務情報
    NBT Bancorp Inc - Strategy, SWOT and Corporate Finance Report Summary NBT Bancorp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Cogstate Ltd (CGS):医療機器:M&Aディール及び事業提携情報
    Summary Cogstate Ltd (Cogstate) is a cognitive science company that provides technology solutions. The company offers scientific consulting, precision recruitment and computerized assessment, among others. It also provides drug development strategies, protocol design, test selection for screening, s …
  • Oglethorpe Power Corporation:企業の戦略・SWOT・財務情報
    Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report Summary Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • ARCA biopharma Inc (ABIO):医療機器:M&Aディール及び事業提携情報
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆